FOURIER: Adding PCSK9 to Statin Therapy Reduces CV Events
Sidney C. Smith, Jr., MD, past president of the American Heart Association, comments on the results of the FOURIER trial. Watch Dr. Smith's take on the global impacts here.
SURTAVI Expands the Treatment Options Available for More Patients
John Warner, MD, president elect of the American Heart Association and Timothy J. Gardner, MD, past president, discuss the results of the SURTAVI trial and what they suggest for the care of patients at varying levels of risk going forward.
Be sure to visit AHA's Scientific Publications booth in the Expo Hall for products and publications designed to help busy cardiovascular professionals and researchers.
- Journal article: Acute Changes in Left Atrial Pressure After MitraClip Are Associated With Improvement in 6-Minute Walk Distance (opens in new window) by Elad Maor, et. al
Circulation: Cardiovascular Interventions
- AHA News Article: Indigenous South American group has the world’s healthiest arteries (opens in new window)
- AHA News Article: Routine blood tests may help predict chronic disease risk (opens in new window)
- AHA News Article: Study: AFib patients may be able to stop blood thinners after ablation (opens in new window)
EINSTEIN CHOICE and GEMINI ACS 1
Mark Creager, MD, past president of the American Heart Association, and Elliott Antman, MD, also a past president, discuss the outcomes of EINSTEIN CHOICE and GEMINI-ACS-1, which compared rivaroxaban to aspirin in different clinical applications.
ABSORB III Results
John Warner, MD, president elect of the American Heart Association, reports on the results of the ABSORB III trial. See a data summary of the trial.
LEVO-CTS: Primary Outcomes for Cardiac Surgery with Levosimendan
Patrick O'Gara, MD, Brigham and Women's Hospital, provides context for the results of the LEVO-CTS trial.